BRILL ANNOUNCES ENTRY INTO THE US PHARMACEUTICAL MARKET STARTING WITH NEW DISRUPTIVE MEDICAL DEVICE IN OPHTHALMOLOGY OF ITS OWN DEVELOPMENT

 

Miami, FL, April 2nd 2024 – BRILL S.L. is a rising pharmaceutical company dedicated to the development, manufacturing and marketing of innovative medical solutions covering essential clinical needs in ophthalmology. Brill is headquartered in Miami and has its manufacturing center in Boston, strategic locations for distributing healthcare solutions throughout the country.

Brill will strongly start its activity in the US by sponsoring several key ophthalmology congresses, such as the AAO (American Academy of Ophthalmology), AAO (American Academy of Optometrist), ASCRS (American Society of Cataract and Refractive Surgery) and TFOS (Tear Film and Ocular Surface Society), among others, in order to support medical and optometric societies.

As part of the strategy to enter and establish the corporation in the USA and specifically in the ophthalmology pharmaceutical market, it is planned to launch several and totally disruptive products, which will clearly improve the ophthalmology clinical practice and the lives of patients. The first product to be launched early in May 2024, among its promising pipeline, is the first and only non-contact and portable Corneal Esthesiometer Brill. This innovative FDA-approved medical device will transform the ophthalmology practice to take the “Complete Ophthalmology Examination” to a new level of efficiency.

The Corneal Esthesiometer Brill measures in a precise and reproducible way the corneal sensitivity, which is a key biomarker to analyze the functional status of the corneal nerves. The cornea is the most densely innervated tissue and is key to the primary protection of the eye and ocular surface, as it is responsible for the blink reflex, the tear production, and the re-epithelialization and wound healing activity in the eye. If there is an alteration in the corneal sensation, means that there is a lack of protection mechanisms and indicates the need for treatment. By being able to analyze corneal sensitivity, ophthalmology doctors will be able to diagnose, monitor and follow up therapies in multiple pathologies in which the corneal nerves are affected.

The European and FDA registrations are a landmark in the field of ophthalmology, as the device will be the first non-invasive esthesiometer available on the worldwide market for the evaluation of corneal-nerve status as a useful biomarker in the diagnosis and prognosis of eye health in highly prevalent diseases, such as glaucoma, herpes and dry

eye, among others. Furthermore, the device will allow ophthalmologists to differentiate stages of diseases such as neurotrophic keratitis, diabetic keratitis and dry eye, and to monitor patients who have undergone refractive surgery or corneal transplants and those who wear contact lenses.

BRILL S.L. has conducted clinical studies at Bascom Palmer Eye Institute, (Miami, Florida), Duke University (Durham, North Carolina), Harvard Medical School (Boston, Massachusetts), Tufts Medical Center (Boston, Massachusetts) and Baylor College of Medicine (Houston, Texas), among other prestigious institutions.

“The Corneal Esthesiometer Brill will allow ophthalmologists and optometrists to detect early stages of corneal sensation loss, allowing us to prescribe more specific treatments and monitor their effectiveness through a non-invasive and cost-effective diagnostic tool.”– Dr. Alfonso Sabater (Ophthalmologist at Bascom Palmer Eye Institute).

Brill is pleased to announce the appointment of Shawn Mullen as Commercial Director of U.S. Eye Health, effective April 1st, 2024. Mr. Mullen brings operational and commercial leadership abilities paired with extensive experience in the Ophthalmic environment for over 25 years. He has established a reputation as an authentic leader with the ability to drive execution through clear organizational vision. “I’m excited to join Brill and be a part of the team that’s known for its commitment to innovation, quality, and excellence. It’s a pioneering business with a solid reputation and culture, best in class technology, with an emphasis on delivering solutions and service to our partners across the Ophthalmic Community for years to come.”

“The worldwide launching of the Corneal Esthesiometer Brill will provide a significant growth in values in 2024 in addition to the funding needed for further investing in and development of unique and innovative products in different therapeutical areas and the strength we need to continue presenting products in different markets during a period of no more than two years.” – Dr. Jordi Martínez Rotllán (founder and CEO of BRILL S.L.).